DE-120

Santen Inc. · Phase 2 active Small molecule

At a glance

Generic name	DE-120
Sponsor	Santen Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration (PHASE1, PHASE2)
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DE-120 CI brief — competitive landscape report
DE-120 updates RSS · CI watch RSS
Santen Inc. portfolio CI